NEW YORK, NY / ACCEESSWIRE / April 18, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
CTLT Shareholders Click Here: https://zlk.com/pslra-1/catalent-class-action-submission-form?prid=38383&wire=1
GOOGL Shareholders Click Here: https://zlk.com/pslra-1/alphabet-lawsuit-submission-form?prid=38383&wire=1
RAD Shareholders Click Here: https://zlk.com/pslra-1/rite-aid-lawsuit-submission-form?prid=38383&wire=1
* ADDITIONAL INFORMATION BELOW *
Catalent, Inc. (NYSE:CTLT)
CTLT Lawsuit on behalf of: investors who purchased August 30, 2021 - October 31, 2022
Lead Plaintiff Deadline: April 25, 2023
TO LEARN MORE, VISIT: https://zlk.com/pslra-1/catalent-class-action-submission-form?prid=38383&wire=1
According to the filed complaint, during the class period, Catalent, Inc. made materially false and/or misleading statements and/or failed to disclose that: a) Catalent materially overstated its revenue and earnings by prematurely recognizing revenue in violation of U.S. Generally Accepted Accounting Principles ("GAAP"); b) Catalent had material weaknesses in its internal control over financial reporting related to revenue recognition; c) Catalent falsely represented demand for its products while it knowingly sold more product to its direct customers than could be sold to healthcare providers and end consumers; d) Catalent disregarded regulatory rules at key production facilities in order to rapidly produce excess inventory that was used to pad the Company's financial results through premature revenue recognition in violation of GAAP and/or stuffing its direct customers with this excess inventory; and e) as a result of the foregoing, defendants lacked a reasonable basis for their positive statements about the Company's financial performance, outlook, and regulatory compliance during the class period.
Alphabet Inc. (NASDAQ:GOOGL)
GOOGL Lawsuit on behalf of: investors who purchased February 4, 2020 - January 23, 2023
Lead Plaintiff Deadline: May 15, 2023
TO LEARN MORE, VISIT: https://zlk.com/pslra-1/alphabet-lawsuit-submission-form?prid=38383&wire=1
According to the filed complaint, during the class period, Alphabet Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Alphabet used its dominance in the field of digital advertising to disadvantage website publishers and advertisers who used competing advertising products; (ii) the foregoing conduct was anticompetitive in nature and likely to draw significant regulatory scrutiny; (iii) Alphabet's revenues were unsustainable to the extent that they were the product of said anticompetitive conduct; (iv) Alphabet's conduct, once revealed, would negatively impact the Company's reputation and expose it to a heightened risk of litigation and regulatory enforcement action; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Rite Aid Corporation (NYSE:RAD)
RAD Lawsuit on behalf of: investors who purchased April 26, 2018 - March 13, 2023
Lead Plaintiff Deadline: May 19, 2023
TO LEARN MORE, VISIT: https://zlk.com/pslra-1/rite-aid-lawsuit-submission-form?prid=38383&wire=1
According to the filed complaint, during the class period, Rite Aid Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) until at least June 2019, Rite Aid filled at least hundreds of thousands of unlawful prescriptions for controlled substances that lacked a legitimate medical purpose, including for potentially lethal opioids such as oxycodone and fentanyl; (2) Rite Aid pharmacists filled these prescriptions despite clear "red flags" that indicated that the prescriptions were unlawful; (3) Rite Aid ignored evidence that its stores were dispensing unlawful prescriptions, and intentionally deleted internal notes about suspicious prescribers written by concerned pharmacists; (4) by knowingly filling unlawful prescriptions for controlled substances, Rite Aid violated the Controlled Substances Act and, where Rite Aid sought reimbursement from federal healthcare programs, also violated the False Claims Act; (5) as a result, it was at risk of prosecution by federal authorities such as the United States Department of Justice; and (6) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 4th Floor Suite #427
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE : Levi & Korsinsky, LLP